Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
Authors Miller J, Ye X, Lenhart GM, M. Farr A, Tran O, Kwong WJ, Magnuson E, Weintraub W
Received 4 November 2015
Accepted for publication 16 January 2016
Published 20 May 2016 Volume 2016:8 Pages 215—226
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Michael Liebman
Peer reviewer comments 4
Editor who approved publication: Professor Giorgio Lorenzo Colombo
Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub4
1Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vascular Health, Christiana Care Health System, Newark, DE, USA
Background: Understanding the value of new anticoagulation therapies compared with existing therapies is of paramount importance in today’s cost-conscious and efficiency-driven health care environment. Edoxaban and rivaroxaban for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with CHADS2 scores ≥2 have been evaluated in pivotal trials versus warfarin. The relative value of edoxaban versus rivaroxaban would be of interest to health care stakeholders and patients who prefer a once-daily treatment option for long-term stroke prevention in NVAF.
Objective: To evaluate the relative cost-effectiveness of two once-daily regimens of novel oral anticoagulation therapy – edoxaban (60 mg/30 mg dose-reduced) versus rivaroxaban (20 mg/15 mg dose-reduced) – for stroke prevention in NVAF patients from a US health-plan perspective.
Materials and methods: A Markov model simulated lifetime risk and treatment of stroke, systemic embolism, major bleeding, clinically relevant nonmajor bleeding, myocardial infarction, and death in NVAF patients treated with edoxaban or rivaroxaban. Efficacy and safety data were derived from a network meta-analysis that utilized data from patients enrolled in ENGAGE AF-TIMI 48 and ROCKET-AF. Health care cost and utility data were obtained from published sources. Incremental cost-effectiveness ratios of $150,000 per quality-adjusted life year (QALY) gained were used as thresholds for “highly cost-effective”, “cost-effective”, and “not cost-effective” treatment options, respectively, as per American Heart Association/American College of Cardiology guidelines.
Results: Edoxaban was dominant relative to rivaroxaban, such that it was associated with lower total health care costs and better effectiveness in terms of QALYs in the base-case analysis. Results were supported by probabilistic sensitivity analyses that showed edoxaban as either dominant or a highly cost-effective alternative (incremental cost-effectiveness ratio <$50,000) to rivaroxaban in 88.4% of 10,000 simulations.
Conclusion: Results of this study showed that the once-daily edoxaban (60 mg/30 mg dose-reduced) regimen is a cost-saving or highly cost-effective treatment relative to rivaroxaban (20 mg/15 mg dose-reduced) for stroke prevention in NVAF patients with CHADS2 ≥2.
Keywords: edoxaban, rivaroxaban, cost-effectiveness, nonvalvular atrial fibrillation, oral anticoagulation, stroke, NOAC, SPAF, economic model, economic analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Economic impact of longer battery life of cardiac resynchronization therapy defibrillators in Sweden
Gadler F, Ding Y, Verin N, Bergius M, Miller JD, Lenhart GM, Russell MW
Published Date: 31 October 2016
Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population
Bonafede MM, Kalra VB, Miller JD, Fajardo LL
Published Date: 12 January 2015
Cost effectiveness of endometrial ablation with the NovaSure® system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives
Miller JD, Lenhart GM, Bonafede MM, Basinski CM, Lukes AS, Troeger KA
Published Date: 6 January 2015
Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
Bonafede MM, Miller JD, Laughlin-Tommaso SK, Lukes AS, Meyer NM, Lenhart GM
Published Date: 8 October 2014